Altered Calcium and Vitamin D in PMDD or Severe PMS
Osteoporosis has become one of the most widely recognized disorders of our times affecting an estimated 25 million women in this country. Recent evidence has suggested that premenstrual syndrome (PMS) is associated with a calcium deficiency state and bone loss. This may place premenopausal women at greater risk for osteoporosis. An entity such as PMS may be an important physiological marker of a...
Brief Summary
Official Title: “Altered Calcium And Vitamin D Metabolism in PMDD”
Osteoporosis has become one of the most widely recognized disorders of our times affecting an estimated 25 million women in this country. Recent evidence has suggested that premenstrual syndrome (PMS) is associated with a calcium deficiency state and bone loss.
This may place premenopausal women at greater risk for osteoporosis. An entity such as PMS may be an important physiological marker of a calcium disturbance. The purpose of this investigation is to understand more completely the extent to which calcium balance is disturbed in severe PMS or Premenstrual Dysphoric Disorder (PMDD) by utilizing new tools to assess calcium and bone turnover. The long term objective is to elucidate the pathophysiology of PMDD or severe PMS as it relates to calcium hormones and bone markers.
The experimental design involves the comparison between women witn severe PMS and asymptomatic controls.
- Study Type: Interventional
- Study Design: Intervention Model: Parallel Assignment, Primary Purpose: Diagnostic
Intervention(s) in this Clinical Trial
- Procedure: Measures of calcium and bone turnover
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Medical history of severe PMS for the PMS group
- No medical history of PMS for the control group
- Prospective 2 month documentation of moderate to severe symptoms for the PMS group
- Prospective 2 month documentation of absent symptoms for the control group
- General good health
- Regular menstrual cycles
- No history of metabolic bone disease
Exclusion Criteria:
- Amenorrhea
- Anorexia nervosa
- Malabsorption
- Inflammatory bowel disease
- Erosive gastrointestinal disease
- Gastrectomy
- Malignancy
- Multiple myeloma
- Primary hyperparathyroidism
- Use of suppressive doses of thyroxine
- Cushing's syndrome
- Use of glucocorticoids or anticonvulsants
- Use of diuretics
- Metabolic bone disease
- Pregnancy or perimenopause or menopause
- Mental retardation
- Menstrual irregularity
- Significant gynecologic abnormality
- Use of birth control pills
Gender Eligibility for this Clinical Trial: Female
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 45 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Investigator Information
Lead Investigator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH
Overall Clinical Trial Officials and Contacts
Susan Thys-Jacobs, MD Principal Investigator St.Luke's-Roosevelt Hospital- Columbia Presbyterian Medical Center
Related Publications
References
Thys-Jacobs, Silverton M, Alvir JM et al. Reduced Bone Mass in women with Premenstrual Syndrome. J Women's Health 1995; 4:161.
Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med. 1989 May-Jun;4(3):183-9.
Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998 Aug;179(2):444-52.
Thys-Jacobs S, Alvir MJ. Calcium-regulating hormones across the menstrual cycle: evidence of a secondary hyperparathyroidism in women with PMS. J Clin Endocrinol Metab. 1995 Jul;80(7):2227-32.
Lee SJ, Kanis JA. An association between osteoporosis and premenstrual symptoms and postmenopausal symptoms. Bone Miner. 1994 Feb;24(2):127-34.
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00005119
Study ID Number: STHYS-JACOBS (completed)
ClinicalTrials.gov Identifier: NCT00005119
Health Authority: United States: Federal Government
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00005119
